Log in

NASDAQ:RVNC - Revance Therapeutics Stock Price, Forecast & News

$25.33
+0.62 (+2.51 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$24.35
Now: $25.33
$25.93
50-Day Range
$15.75
MA: $21.09
$26.92
52-Week Range
$9.88
Now: $25.33
$27.06
Volume778,858 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:RVNC
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees170
Next Earnings Date2/24/2020 (Confirmed)
OptionableOptionable

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.


Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) posted its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.96). The biopharmaceutical company earned $0.05 million during the quarter, compared to the consensus estimate of $0.40 million. View Revance Therapeutics' Earnings History.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Revance Therapeutics.

How can I listen to Revance Therapeutics' earnings call?

Revance Therapeutics will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for RVNC?

7 equities research analysts have issued 1-year price objectives for Revance Therapeutics' shares. Their forecasts range from $20.00 to $39.00. On average, they expect Revance Therapeutics' stock price to reach $27.33 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.

What is the consensus analysts' recommendation for Revance Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:
  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (1/15/2020)
  • 2. Mizuho analysts commented, "We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT." (4/24/2019)

Has Revance Therapeutics been receiving favorable news coverage?

Media stories about RVNC stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Revance Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Revance Therapeutics.

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totalling 6,590,000 shares, an increase of 9.8% from the December 31st total of 6,000,000 shares. Based on an average daily trading volume, of 661,200 shares, the days-to-cover ratio is currently 10.0 days. Approximately 16.9% of the company's stock are sold short. View Revance Therapeutics' Current Options Chain.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Myovant Sciences (MYOV), Bristol-Myers Squibb (BMY), Merck & Co., Inc. (MRK), Fate Therapeutics (FATE) and Global Blood Therapeutics (GBT).

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:
  • Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 56)
  • Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (10.73%), Franklin Resources Inc. (7.94%), Rice Hall James & Associates LLC (2.36%), State Street Corp (2.34%), Perceptive Advisors LLC (1.82%) and Renaissance Technologies LLC (1.50%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.

Which major investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Candriam Luxembourg S.C.A., Nisa Investment Advisors LLC, Rice Hall James & Associates LLC, Citigroup Inc. and Bank of America Corp DE. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche and L Daniel Browne. View Insider Buying and Selling for Revance Therapeutics.

Which major investors are buying Revance Therapeutics stock?

RVNC stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Alyeska Investment Group L.P., EAM Global Investors LLC, Sei Investments Co., Knights of Columbus Asset Advisors LLC, EAM Investors LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Revance Therapeutics.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $25.33.


MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  329 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  640
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel